S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
66,000% upside on tiny biotech? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The single greatest medical breakthrough of all time? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
66,000% upside on tiny biotech? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The single greatest medical breakthrough of all time? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
66,000% upside on tiny biotech? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The single greatest medical breakthrough of all time? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
66,000% upside on tiny biotech? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The single greatest medical breakthrough of all time? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people

Agios Pharmaceuticals (AGIO) Stock Forecast, Price & News

$24.53
-0.37 (-1.49%)
(As of 09/22/2023 ET)
Compare
Today's Range
$24.40
$25.04
50-Day Range
$24.53
$28.17
52-Week Range
$21.07
$31.87
Volume
223,034 shs
Average Volume
328,958 shs
Market Capitalization
$1.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.00

Agios Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
46.8% Upside
$36.00 Price Target
Short Interest
Bearish
11.04% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.53
Upright™ Environmental Score
News Sentiment
1.61mentions of Agios Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$1.65 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($6.29) to ($4.70) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

513th out of 963 stocks

Pharmaceutical Preparations Industry

237th out of 458 stocks


AGIO stock logo

About Agios Pharmaceuticals (NASDAQ:AGIO) Stock

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

AGIO Price History

AGIO Stock News Headlines

Nektar Therapeutics (NKTR) Gets a Sell from Bank of America Securities
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
J.P. Morgan Reaffirms Their Hold Rating on Sana Biotechnology (SANA)
Agios Pharmaceuticals Inc (8AP.BE)
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Here's what Wall Street expects from Agios Pharmaceuticals's earnings
See More Headlines
Receive AGIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AGIO Company Calendar

Last Earnings
8/03/2023
Today
9/24/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AGIO
Fax
N/A
Employees
389
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$36.00
High Stock Price Forecast
$41.00
Low Stock Price Forecast
$32.00
Forecasted Upside/Downside
+46.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-231,800,000.00
Net Margins
-1,042.56%
Pretax Margin
-1,042.56%

Debt

Sales & Book Value

Annual Sales
$14.24 million
Book Value
$20.03 per share

Miscellaneous

Free Float
53,376,000
Market Cap
$1.37 billion
Optionable
Optionable
Beta
0.95
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Brian M. Goff M.B.A. (Age 54)
    CEO & Director
    Comp: $1.23M
  • Ms. Cecilia Jones (Age 48)
    Chief Financial Officer
    Comp: $403.36k
  • Mr. James William Burns (Age 45)
    Corp. Sec. & Chief Legal Officer
    Comp: $660.33k
  • Dr. Sarah Gheuens M.D. (Age 43)
    Ph.D., Chief Medical Officer and Head of R&D
    Comp: $769.2k
  • Dr. Lewis Clayton Cantley Ph.D. (Age 74)
    Co-Founder & Member of Scientific Advisory Board
  • Dr. Tak Wah Mak D.Sc. (Age 77)
    FRSC, Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Dr. Craig B. Thompson M.D. (Age 70)
    Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Shin-San Su Ph.D. (Age 67)
    Co-Founder & Member of Scientific Advisory Board
  • Mr. T. J. Washburn Jr. (Age 42)
    Principal Accounting Officer
  • Dr. Clive Patience Ph.D. (Age 59)
    Chief Technical Operations Officer













AGIO Stock - Frequently Asked Questions

Should I buy or sell Agios Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AGIO shares.
View AGIO analyst ratings
or view top-rated stocks.

What is Agios Pharmaceuticals' stock price forecast for 2023?

4 Wall Street analysts have issued 1 year price targets for Agios Pharmaceuticals' shares. Their AGIO share price forecasts range from $32.00 to $41.00. On average, they anticipate the company's stock price to reach $36.00 in the next year. This suggests a possible upside of 46.8% from the stock's current price.
View analysts price targets for AGIO
or view top-rated stocks among Wall Street analysts.

How have AGIO shares performed in 2023?

Agios Pharmaceuticals' stock was trading at $28.08 at the beginning of the year. Since then, AGIO shares have decreased by 12.6% and is now trading at $24.53.
View the best growth stocks for 2023 here
.

When is Agios Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our AGIO earnings forecast
.

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced its quarterly earnings data on Thursday, August, 3rd. The biopharmaceutical company reported ($1.51) earnings per share for the quarter, beating analysts' consensus estimates of ($1.60) by $0.09. The biopharmaceutical company had revenue of $6.70 million for the quarter, compared to the consensus estimate of $6.46 million. Agios Pharmaceuticals had a negative net margin of 1,042.56% and a negative trailing twelve-month return on equity of 20.24%. The business's quarterly revenue was up 20.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.68) earnings per share.

What ETFs hold Agios Pharmaceuticals' stock?
What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO?

11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), Tesla (TSLA) and Netflix (NFLX).

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Who are Agios Pharmaceuticals' major shareholders?

Agios Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.48%), Rock Springs Capital Management LP (4.82%), State Street Corp (4.63%), JPMorgan Chase & Co. (4.47%), Dimensional Fund Advisors LP (4.06%) and ArrowMark Colorado Holdings LLC (2.82%). Insiders that own company stock include Brian Goff, Carman Alenson, Cecilia Jones, Christopher Bowden, Darrin Miles, David P Schenkein, Jacqualyn A Fouse, James William Burns, Kaye I Foster-Cheek and Theodore James Jr Washburn.
View institutional ownership trends
.

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agios Pharmaceuticals' stock price today?

One share of AGIO stock can currently be purchased for approximately $24.53.

How much money does Agios Pharmaceuticals make?

Agios Pharmaceuticals (NASDAQ:AGIO) has a market capitalization of $1.37 billion and generates $14.24 million in revenue each year. The biopharmaceutical company earns $-231,800,000.00 in net income (profit) each year or ($3.80) on an earnings per share basis.

How many employees does Agios Pharmaceuticals have?

The company employs 389 workers across the globe.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.agios.com. The biopharmaceutical company can be reached via phone at (617) 649-8600 or via email at investors@agios.com.

This page (NASDAQ:AGIO) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -